Anti-vascular endothelial growth factor antibody attenuates inflammation and decreases mortality in an experimental model of severe sepsis

Critical Care

Volumn 17, Issue 3, 2013, Pages

  Jeong, Su Jin ^a   Han, Sang Hoon ^a   Kim, Chang Oh ^a   Choi, Jun Yong ^a   Kim, June Myung ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

anti VEGF antibody; bevacizumab; sepsis; vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CYTOKINE; LIPOPOLYSACCHARIDE; MESSENGER RNA; TOLL LIKE RECEPTOR 4; TROVAFLOXACIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CECAL LIGATION AND PUNCTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOTOXEMIA; EXPERIMENTAL MODEL; FLUID RESUSCITATION; HUMAN; HUMAN CELL; INFLAMMATION; KIDNEY; LIGATION; LUNG; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUNCTURE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEPSIS; SIGNAL TRANSDUCTION; SPLEEN; SUPERNATANT; SURVIVAL; UMBILICAL VEIN ENDOTHELIAL CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; METABOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE MODELS, ANIMAL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; SEPSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84878100263     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc12742     Document Type: Article

References (39)

1. Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med 1996, 24:1431-1440. 10.1097/00003246-199609000-00002, 8797612.
2. Abraham E, Anzueto A, Gutierrez G, Tessler S, San Pedro G, Wunderink R, Dal Nogare A, Nasraway S, Berman S, Cooney R, Levy H, Baughman R, Rumbak M, Light RB, Poole L, Allred R, Constant J, Pennington J, Porter S. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998, 351:929-933.
3. Ranieri VM, Thompson BT, Barie PS, Dhainaut J, Douglas IS, Finfer S, Gãrdlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012, 366:2055-2064. 10.1056/NEJMoa1202290, 22616830.
4. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985. 10.1126/science.6823562, 6823562.
5. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306-1309. 10.1126/science.2479986, 2479986.
6. Kuenen BC, Levi M, Meijers JC, Kakkar AK, van Hinsbergh VW, Kostense PJ, Pinedo HM, Hoekman K. Analysis of coagulation cascade and endothelial cell activation during inhibition of vascular endothelial growth factor/vascular endothelial growth factor receptor pathway in cancer patients. Arterioscler Thromb Vasc Biol 2002, 22:1500-1505. 10.1161/01.ATV.0000030186.66672.36, 12231573.
7. Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Biochem Soc Trans 2003, 31:20-24.
8. Kim I, Moon SO, Kim SH, Kim HJ, Koh YS, Koh GY. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 2001, 276:7614-7620. 10.1074/jbc.M009705200, 11108718.
9. Reinders ME, Sho M, Izawa A, Wang P, Mukhopadhyay D, Koss KE, Geehan CS, Luster AD, Sayegh MH, Briscoe DM. Proinflammatory functions of vascular endothelial growth factor in alloimmunity. J Clin Invest 2003, 112:1655-1665. 281640, 14660742.
10. Lucerna M, Mechtcheriakova D, Kadl A, Schabbauer G, Schäfer R, Gruber F, Koshelnick Y, Müller H, Issbrücker K, Clauss M, Binder BR, Hofer E. NAB2, a corepressor of EGR-1, inhibits vascular endothelial growth factor-mediated gene induction and angiogenic responses of endothelial cells. J Biol Chem 2003, 278:11433-11440. 10.1074/jbc.M204937200, 12427750.
11. Pickkers P, Sprong T, van Eijk L, van der Hoeven H, Smits P, van Deuren M. Vascular endothelial growth factor is increased during the first 48 hours of human septic shock and correlates with vascular permeability. Shock 2005, 24:508-512. 10.1097/01.shk.0000190827.36406.6e, 16317379.
12. van der Flier M, van Leeuwen HJ, van Kessel KP, Kimpen JL, Hoepelman AI, Geelen SP. Plasma vascular endothelial growth factor in severe sepsis. Shock 2005, 23:35-38. 10.1097/01.shk.0000150728.91155.41, 15614129.
13. Ferrara N, Hillan KJ, Gerber H, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004, 3:391-400. 10.1038/nrd1381, 15136787.
14. Shojaei F, Ferrara N. Antiangiogenesis to treat cancer and intraocular neovascular disorders. Lab Invest 2007, 87:227-230. 10.1038/labinvest.3700526, 17259997.
15. Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic Surg Lasers Imaging 2005, 36:336-339.
16. Rice L, Orlow D, Ceonzo K, Stahl GL, Tzianabos AO, Wada H, Aird WC, Buras JA. CpG oligodeoxynucleotide protection in polymicrobial sepsis is dependent on interleukin-17. J Infect Dis 2005, 191:1368-1376. 10.1086/428452, 15776385.
17. Yano K, Liaw PC, Mullington JM, Shih S, Okada H, Bodyak N, Kang PM, Toltl L, Belikoff B, Buras J, Simms BT, Mizgerd JP, Carmeliet P, Karumanchi SA, Aird WC. Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med 2006, 203:1447-1458. 10.1084/jem.20060375, 2118329, 16702604.
18. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K, Isner JM. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998, 97:1114-1123. 10.1161/01.CIR.97.12.1114, 9537336.
19. Harada M, Mitsuyama K, Yoshida H, Sakisaka S, Taniguchi E, Kawaguchi T, Ariyoshi M, Saiki T, Sakamoto M, Nagata K, Sata M, Matsuo K, Tanikawa K. Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 1998, 27:377-380. 10.1080/03009749850154429, 9808403.
20. Taha Y, Raab Y, Larsson A, Carlson M, Lööf L, Gerdin B, Thörn M. Vascular endothelial growth factor (VEGF)--a possible mediator of inflammation and mucosal permeability in patients with collagenous colitis. Dig Dis Sci 2004, 49:109-115.
21. Rice TW, Bernard GR. Therapeutic intervention and targets for sepsis. Annu Rev Med 2005, 56:225-248. 10.1146/annurev.med.56.082103.104356, 15660511.
22. Cross AS, Opal SM. A new paradigm for the treatment of sepsis: is it time to consider combination therapy?. Ann Intern Med 2003, 138:502-505. 10.7326/0003-4819-138-6-200303180-00016, 12639085.
23. Streck EL, Comim CM, Barichello T, Quevedo J. The septic brain. Neurochem Res 2008, 33:2171-2177. 10.1007/s11064-008-9671-3, 18461451.
24. Wang H, Ma S. The cytokine storm and factors determining the sequence and severity of organ dysfunction in multiple organ dysfunction syndrome. Am J Emerg Med 2008, 26:711-715. 10.1016/j.ajem.2007.10.031, 18606328.
25. Lundy DJ, Trzeciak S. Microcirculatory dysfunction in sepsis. Crit Care Nurs Clin North Am 2011, 23:67-77. 10.1016/j.ccell.2010.12.004, 21316568.
26. Veszelka S, Pásztói M, Farkas AE, Krizbai I, Ngo TK, Niwa M, Abrahám CS, Deli MA. Pentosan polysulfate protects brain endothelial cells against bacterial lipopolysaccharide-induced damages. Neurochem Int 2007, 50:219-228. 10.1016/j.neuint.2006.08.006, 16997427.
27. Birnbaum J, Hein OV, Lührs C, Rückbeil O, Spies C, Ziemer S, Gründling M, Usichenko T, Meissner K, Pavlovic D, Kox WJ, Lehmann C. Effects of coagulation factor XIII on intestinal functional capillary density, leukocyte adherence and mesenteric plasma extravasation in experimental endotoxemia. Crit Care 2006, 10:R29-R29. 10.1186/cc3994, 1550842, 16507148.
28. Lehmann C, Birnbaum J, Lührs C, Rückbeil O, Spies C, Ziemer S, Gründling M, Pavlovic D, Usichenko T, Wendt M, Kox WJ. Effects of C1 esterase inhibitor administration on intestinal functional capillary density, leukocyte adherence and mesenteric plasma extravasation during experimental endotoxemia. Intensive Care Med 2004, 30:309-314. 10.1007/s00134-003-2042-2, 14586496.
29. Tsao P, Chan F, Wei S, Hsieh W, Chou H, Su Y, Chen C, Hsu W, Hsieh F, Hsu S. Soluble vascular endothelial growth factor receptor-1 protects mice in sepsis. Crit Care Med 2007, 35:1955-1960. 10.1097/01.CCM.0000275273.56547.B8, 17568329.
30. Nolan A, Weiden MD, Thurston G, Gold JA. Vascular endothelial growth factor blockade reduces plasma cytokines in a murine model of polymicrobial sepsis. Inflammation 2004, 28:271-278. 10.1007/s10753-004-6050-3, 3417046, 16134000.
31. Kaner RJ, Ladetto JV, Singh R, Fukuda N, Matthay MA, Crystal RG. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol 2000, 22:657-664. 10.1165/ajrcmb.22.6.3779, 10837361.
32. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593-4599.
33. Cornacoff JB, Howk K, Pikounis B, Mendenhall V, Martin P. Development of a method for the evaluation of wound tensile strength in cynomolgus macaques. J Pharmacol Toxicol Methods 2008, 57:74-79. 10.1016/j.vascn.2007.08.002, 17900932.
34. Hendriks JM, Hubens G, Wuyts FL, Vermeulen P, Hubens A, Eyskens E. Experimental study of intraperitoneal suramin on the healing of colonic anastomoses. Br J Surg 1999, 86:1171-1175. 10.1046/j.1365-2168.1999.01223.x, 10504372.
35. Howdieshell TR, Callaway D, Webb WL, Gaines MD, Procter CD, Sathyanarayana JS, Pollock TL, Brock PL, McNeil PL. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. J Surg Res 2001, 96:173-182. 10.1006/jsre.2001.6089, 11266270.
36. te Velde EA, Voest EE, van Gorp JM, Verheem A, Hagendoorn J, Gebbink MF, Borel Rinkes IH. Adverse effects of the antiangiogenic agent angiostatin on the healing of experimental colonic anastomoses. Ann Surg Oncol 2002, 9:303-309.
37. Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn L, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino Kenudson M, Lauwers GY. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005, 23:8136-8139. 10.1200/JCO.2005.02.5635, 16258121.
38. Lee CG, Heijn M, di Tomaso E, Griffon Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, Boucher Y. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000, 60:5565-5570.
39. Gerber HP, Kowalski J, Sherman D, Eberhard DA, Ferrara N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res 2000, 60:6253-6258.